 CAMBRIDGE, Mass., March 10, 2021 GLOBE NEWSWIRE -- Surface Oncology Nasdaq: SURF, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced two scientific e-posters sharing updated preclinical data will be presented at the American Association for Cancer Research AACR 2021 Annual Meeting, to be held virtually April 10-15 and May 17-21, 2021. 